Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.
Full description
Primary Objective:
-To evaluate the efficacy of lonca as consolidation therapy in patients with relapsed or refractory LBCL who achieve PR after CAR T-cell therapy.
Secondary Objectives:
-To evaluate safety and tolerability of lonca as consolidation therapy in patients with relapsed or refractory LBCL who achieve PR after CAR T-cell therapy.
Exploratory Objective:
-To determine the pharmacodynamic effects and investigate biomarkers of response and resistance of this novel consolidation therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Eligible subjects will be considered for inclusion in this study if they meet the following criteria:
4.3 Exclusion criteria
Subjects will be ineligible for this study if they meet the following criteria:
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Central trial contact
Paolo Strati, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal